Plasminogen Activator Inhibitor-1 and the Calculus of Mortality After Myocardial Infarction
2003; Lippincott Williams & Wilkins; Volume: 108; Issue: 4 Linguagem: Inglês
10.1161/01.cir.0000082929.85234.e7
ISSN1524-4539
Autores Tópico(s)Protease and Inhibitor Mechanisms
ResumoHomeCirculationVol. 108, No. 4Plasminogen Activator Inhibitor-1 and the Calculus of Mortality After Myocardial Infarction Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBPlasminogen Activator Inhibitor-1 and the Calculus of Mortality After Myocardial Infarction Douglas E. Vaughan, MD Douglas E. VaughanDouglas E. Vaughan From the Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tenn. Originally published29 Jul 2003https://doi.org/10.1161/01.CIR.0000082929.85234.E7Circulation. 2003;108:376–377There are numerous clinical factors that have been identified that are associated with an adverse outcome after acute myocardial infarction (MI). These factors include female gender, the presence of severe left ventricular dysfunction or congestive heart failure, a history of diabetes mellitus, age >70 years, infarct location (anterior versus inferior), and patency of the infarct-related artery. In this issue of Circulation, Collet and colleagues1 describe a previously unrecognized relationship between acute increases in plasma levels of plasminogen activator inhibitor-1 (PAI-1) in patients hospitalized with acute ST-elevation MI and risk of mortality during a 1-month period.See p 391PAI-1 is the primary circulating inhibitor of tissue-type plasminogen activator and the urokinase-type plasminogen activator in plasma. Elevated plasma PAI-1 levels have been shown to be a predictor of recurrent MI2 and have been identified as an independent predictor of cardiovascular risk.3 When one considers the many factors that regulate plasma PAI-1 levels, it is not completely surprising that acute increases in the levels of PAI-1 in plasma might reflect increased risk of mortality after acute MI. The PAI-1 that circulates in plasma is derived from the composite output of several different cellular synthetic sites, including the liver, the vascular endothelium, and visceral adipose tissue. There are a number of factors that are known to directly affect PAI-1 production, including metabolic factors such as glucose,4 insulin,5 and VLDL,6 neurohumoral factors including angiotensin II and aldosterone,7,8 and inflammatory cytokines including tumor necrosis factor-α9 and interleukin-1.10 The remarkable relationship described in this study could reflect the impact of any or all of the previously listed mechanisms. For example, it has been shown previously that impaired glucose control is an independent predictor of risk after acute MI.11 Although the level of metabolic control in this population is not described, it certainly is possible that some of the mortality associated with elevated PAI-1 levels reported here may simply reflect poor glycemic control in the peri-infarct setting. PAI-1 is commonly and predictably elevated in individuals with insulin resistance and type II diabetes, and whereas diabetics made up ≈19% of the population studied here, it is not clear whether they were overrepresented with regard to 1-month mortality.Our group and others have shown a strong relationship between activation of the renin-angiotensin-aldosterone system (RAAS) and plasma PAI-1.12,13 It is known that the RAAS is activated after acute MI.14 The level of activation of the RAAS can also reflect the extent and severity of left ventricular dysfunction after acute anterior MI.15 In this context, PAI-1 may represent a circulating marker of activation of the RAAS that may be indirectly related to infarct size. PAI-1 is also a classic acute phase reactant and is strongly upregulated by inflammatory cytokines. Healing after MI involves an inflammatory process that is generally thought to occur later in the course of events after an MI, a process temporally delayed from the early increase in PAI-1 seen in this study, although some inflammatory contribution to these acute increases cannot be excluded.There are several important limitations to this study. The population examined is relatively small in size, which precludes any definitive conclusions being drawn at present. The novelty of the associations suggests that these observations deserve to be validated in larger and better-characterized populations. Although the authors were successful in identifying a change in plasma PAI-1 as a predictor of risk, it is surprising that the well-known circadian variation patterns in plasma PAI-116 did not confound the results or diminish the differences between subjects who survived and those who died. There is also no accompanying information on the potential benefit of therapies, both pharmacological and nonpharmacological, that might prevent the acute increase in plasma PAI-1. These potentially include ACE inhibitors,17 insulin synthesizing agents,18 or other agents that improve endothelial function and nitric oxide production systematically.Overall, this study suggests that the acute release of PAI-1 in ST-elevation MI helps identify patients at risk for undesirable outcomes. The novelty and statistical strength of the association reported are noteworthy and should provide a strong impetus for further investigation. It is tempting to speculate that additional therapeutic measures that reduce PAI-1 production or directly antagonize PAI-1 activity may eventually be of value in the setting of acute MI.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.FootnotesCorrespondence to Douglas E. Vaughan, MD, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Room 383 PRB, 2220 Pierce Ave, Nashville, TN 37232-6300. E-mail [email protected] References 1 Collet JP, Montalescot G, Vicaut E, et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation. 2003; 108: 391–394.LinkGoogle Scholar2 Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987; 2: 3–9.CrossrefMedlineGoogle Scholar3 Thogersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 1998; 98: 2241–2247.CrossrefMedlineGoogle Scholar4 Nordt TK, Klassen KJ, Schneider DJ, et al. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb. 1993; 13: 1822–1828.CrossrefMedlineGoogle Scholar5 Nordt TK, Sawa H, Fujii S, et al. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation. 1995; 91: 764–770.CrossrefMedlineGoogle Scholar6 Eriksson P, Nilsson L, Karpe F, et al. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 1998; 18: 20–26.CrossrefMedlineGoogle Scholar7 Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest. 1995; 95: 995–1001.CrossrefMedlineGoogle Scholar8 Brown NJ, Kim KS, Chen YQ, et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab. 2000; 85: 336–344.MedlineGoogle Scholar9 Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo: tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest. 1991; 88: 1346–1353.CrossrefMedlineGoogle Scholar10 Bevilacqua MP, Schleef RR, Gimbrone MA Jr, et al. Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1. J Clin Invest. 1986; 78: 587–591.CrossrefMedlineGoogle Scholar11 Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995; 26: 57–65.CrossrefMedlineGoogle Scholar12 Brown NJ, Gainer JV, Stein CM, et al. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension. 1998; 32: 965–971.CrossrefMedlineGoogle Scholar13 Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension. 1999; 34: 285–290.CrossrefMedlineGoogle Scholar14 Rouleau JL, Moye LA, de Champlain J, et al. Activation of neurohumoral systems following acute myocardial infarction. Am J Cardiol. 1991; 68: 80D–86D.CrossrefMedlineGoogle Scholar15 Vaughan DE, Lamas GA, Pfeffer MA. Role of left ventricular dysfunction in selective neurohumoral activation in the recovery phase of anterior wall acute myocardial infarction. Am J Cardiol. 1990; 66: 529–532.CrossrefMedlineGoogle Scholar16 Andreotti F, Kluft C. Circadian variation of fibrinolytic activity in blood. Chronobiol Int. 1991; 8: 336–351.CrossrefMedlineGoogle Scholar17 Vaughan DE, Rouleau J-L, Ridker PM, et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation. 1997; 96: 442–447.CrossrefMedlineGoogle Scholar18 Vague P, Juhan-Vague I, Alessi MC, et al. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost. 1987; 57: 326–328.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Montrezol F, Marinho R, Mota G, D'almeida V, de Oliveira E, Gomes R and Medeiros A (2019) ACE Gene Plays a Key Role in Reducing Blood Pressure in The Hyperintensive Elderly After Resistance Training, Journal of Strength and Conditioning Research, 10.1519/JSC.0000000000002355, 33:4, (1119-1129), Online publication date: 1-Apr-2019. Akhter M, Biswas A, Abdullah S, Behari M and Saxena R (2017) The Role of PAI-1 4G/5G Promoter Polymorphism and Its Levels in the Development of Ischemic Stroke in Young Indian Population, Clinical and Applied Thrombosis/Hemostasis, 10.1177/1076029617705728, 23:8, (1071-1076), Online publication date: 1-Nov-2017. Hu X, Zan X, Xie Z, Li Y, Lin S, Li H and You C (2016) Association Between Plasminogen Activator Inhibitor-1 Genetic Polymorphisms and Stroke Susceptibility, Molecular Neurobiology, 10.1007/s12035-015-9549-8, 54:1, (328-341), Online publication date: 1-Jan-2017. Luo M, Li R, Ren M, Chen N, Deng X, Tan X, Li Y, Zeng M, Yang Y, Wan Q and Wu J (2016) Hyperglycaemia-induced reciprocal changes in miR-30c and PAI-1 expression in platelets, Scientific Reports, 10.1038/srep36687, 6:1, Online publication date: 23-Dec-2016. Velagapudi P, Turagam M, Agrawal H, Mittal M, Kocheril A and Aggarwal K (2014) Antithrombotics in atrial fibrillation and coronary disease, Expert Review of Cardiovascular Therapy, 10.1586/14779072.2014.937427, 12:8, (977-986), Online publication date: 1-Aug-2014. Figueras J, Monasterio J, Domingo E, Meneses B, Nieto E, Cortadellas J and Garcia-Dorado D (2011) Prothrombotic profile in patients with vasospastic or non vasospastic angina and non significant coronary stenosis, Thrombosis Journal, 10.1186/1477-9560-9-10, 9:1, (10), . Di Minno M, Pezzullo S, Palmieri V, Di Somma C, Lupoli R, Valle D, Lombardi G and Di Minno G (2010) Protein C and protein S changes in GH-deficient adults on r-HGH replacement therapy, Thrombosis Research, 10.1016/j.thromres.2010.08.028, 126:6, (e434-e438), Online publication date: 1-Dec-2010. Binder B and Prager G (2010) Extravasale Proteolyse: Funktion und Interaktion der Faktoren des fibrinolytischen Systems Hämostaseologie, 10.1007/978-3-642-01544-1_30, (289-299), . Valle D, Di Minno M, Palmieri V, Pezzullo S, Cirillo F, Di Somma C, Di Mirino G and Lombardi G (2009) Changes in insulin levels following 6-month treatment with recombinant human growth hormone in growth hormone-deficient adults, Journal of Endocrinological Investigation, 10.1007/BF03345771, 32:11, (908-912), Online publication date: 1-Dec-2009. Di Minno M, Palmieri V, Lombardi G, Pezzullo S, Cirillo F, Di Somma C, Valle D and Di Minno G (2009) Lack of change in insulin levels as a biological marker of PAI-1 lowering in GH-deficient adults on r-HGH replacement therapy, Thrombosis Research, 10.1016/j.thromres.2009.06.018, 124:6, (711-713), Online publication date: 1-Dec-2009. de Ferranti S and Rifai N (2007) C-reactive protein: a nontraditional serum marker of cardiovascular risk, Cardiovascular Pathology, 10.1016/j.carpath.2006.04.006, 16:1, (14-21), Online publication date: 1-Jan-2007. Devin J, Blevins L, Verity D, Chen Q, Bloodworth J, Covington J and Vaughan D (2007) Markedly Impaired Fibrinolytic Balance Contributes to Cardiovascular Risk in Adults with Growth Hormone Deficiency, The Journal of Clinical Endocrinology & Metabolism, 10.1210/jc.2007-0609, 92:9, (3633-3639), Online publication date: 1-Sep-2007. Brown N, Muldowney J and Vaughan D (2006) Endogenous NO Regulates Plasminogen Activator Inhibitor-1 During Angiotensin-Converting Enzyme Inhibition, Hypertension, 47:3, (441-448), Online publication date: 1-Mar-2006. Libby P (2006) Inflammation in Cardiovascular Disease Cardiovascular Biomarkers, 10.1007/978-1-59745-051-5_14, (207-221), . Libby P and Ridker P (2006) Inflammation and Atherothrombosis, Journal of the American College of Cardiology, 10.1016/j.jacc.2006.08.011, 48:9, (A33-A46), Online publication date: 1-Nov-2006. Libby P and Theroux P (2005) Pathophysiology of Coronary Artery Disease, Circulation, 10.1161/CIRCULATIONAHA.105.537878, 111:25, (3481-3488), Online publication date: 28-Jun-2005. July 29, 2003Vol 108, Issue 4 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000082929.85234.E7PMID: 12885727 Originally publishedJuly 29, 2003 Keywordsmyocardial infarctionEditorialsmortalityPDF download Advertisement
Referência(s)